Electrophysiological effects of sotalol--just another beta blocker?
- PMID: 7082499
- PMCID: PMC481176
- DOI: 10.1136/hrt.47.6.515
Electrophysiological effects of sotalol--just another beta blocker?
Abstract
The electrophysiological effects of intravenous sotalol hydrochloride (0.4 mg/kg) were assessed in 24 patients, including 13 with the Wolff-Parkinson-White syndrome, undergoing routine electrophysiological study. Fifteen to 30 minutes after sotalol administration there was a significant increase in sinus cycle length and in sinus node recovery time. There was a small increase in the AH interval, but the HV interval was unchanged. The QT and JT intervals, measured during sinus rhythm, were both increased. The atrial, ventricular, and atrioventricular nodal effective refractory periods were all prolonged, as was the atrioventricular nodal functional refractory period. In 13 patients with ventricular pre-excitation there was an increase of the accessory pathway anterograde and retrograde effective refractory periods. In 12 of these 13 sotalol was given during atrioventricular re-entrant tachycardia, resulting in termination in five. Tachycardia cycle length increased in all patients, with the major effect being in the atrioventricular direction. Though some of the effects seen in these patients are consistent with the beta adrenergic antagonist properties of sotalol, the effect on atrial, ventricular, and accessory pathway effective refractory periods and on ventricular repolarisation is not typical of that observed with other beta blockers but may be the result of lengthening of the action potential duration. These findings suggest that sotalol may be a more versatile antiarrhythmic agent than other beta receptor antagonists.
Similar articles
-
[Sotalol in supraventricular tachycardia. Electrophysiologic measurements in Wolff-Parkinson-White syndrome and AV node re-entry tachycardia].Z Kardiol. 1985 Sep;74(9):500-5. Z Kardiol. 1985. PMID: 4060827 German.
-
Effects of intravenous sotalol in patients with atrioventricular accessory pathways.Am Heart J. 1987 Sep;114(3):545-50. doi: 10.1016/0002-8703(87)90751-4. Am Heart J. 1987. PMID: 3630895
-
[Electrophysiologic effect of sotalol in supraventricular tachycardias].Z Kardiol. 1985 Sep;74(9):506-11. Z Kardiol. 1985. PMID: 4060828 German.
-
Electrophysiologic properties of sotalol and d-sotalol. A current view.Eur Heart J. 1993 Nov;14 Suppl H:24-9. doi: 10.1093/eurheartj/14.suppl_h.24. Eur Heart J. 1993. PMID: 7904935 Review.
-
Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.Drugs. 1995 May;49(5):664-79. doi: 10.2165/00003495-199549050-00003. Drugs. 1995. PMID: 7601009 Review.
Cited by
-
Efficacy of oral sotalol in reentrant ventricular tachycardia.Cardiovasc Drugs Ther. 1990 Jun;4 Suppl 3:613-8. doi: 10.1007/BF00357039. Cardiovasc Drugs Ther. 1990. PMID: 2275891 Clinical Trial.
-
Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.Drugs. 1987 Sep;34(3):311-49. doi: 10.2165/00003495-198734030-00002. Drugs. 1987. PMID: 3315621 Review.
-
Successful termination of combined rapid atrial flutter/fibrillation and ventricular tachycardia by intravenous sotalol.Postgrad Med J. 1987 Jul;63(741):579-80. doi: 10.1136/pgmj.63.741.579. Postgrad Med J. 1987. PMID: 3658868 Free PMC article.
-
Effect of long term treatment with metoprolol and sotalol on ventricular repolarisation measured by use of transoesophageal atrial pacing.Br Heart J. 1986 Feb;55(2):181-6. doi: 10.1136/hrt.55.2.181. Br Heart J. 1986. PMID: 3080012 Free PMC article. Clinical Trial.
-
QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.Cardiovasc Drugs Ther. 1991 Apr;5(2):515-30. doi: 10.1007/BF03029779. Cardiovasc Drugs Ther. 1991. PMID: 1854661 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources